GLP-1 receptor agonist drugs — including Novo Nordisk's Ozempic, Wegovy, and Rybelsus, and Eli Lilly's Mounjaro and Zepbound — have generated over $40 billion in annual sales while allegedly causing severe gastrointestinal injuries that manufacturers failed to adequately disclose. Over 3,100 lawsuits are consolidated in MDL 3094 in the Eastern District of Pennsylvania, with a separate NAION vision-loss MDL (3163) established in December 2025.
Litigation Timeline
NAION Vision-Loss MDL Established
JPML establishes MDL 3163 for NAION vision-loss claims against Novo Nordisk. Approximately 29 cases consolidated with rapid growth expected. Expert discovery ongoing in the GI MDL; bellwether trials expected mid-2026.
filingJudge Marston Ruling on Gastric Emptying Studies
MDL judge rules that gastroparesis plaintiffs must have a properly performed gastric emptying study confirming delayed emptying at time of diagnosis. May narrow plaintiff pool but strengthens remaining cases.
filingFDA Updates Ozempic Label for Gastroparesis
FDA updates Ozempic label to state drug is "not recommended in patients with severe gastroparesis" and adds intestinal obstruction warning — the first explicit gastroparesis language on the label.
regulatoryJAMA Study Links Semaglutide to Vision Loss
JAMA Ophthalmology study finds semaglutide users face dramatically elevated NAION risk (8.9% vs 1.8% in diabetic patients). EMA requires European label update in August 2024; Novo Nordisk does not update U.S. labels.
scientificMDL 3094 Established
The JPML consolidates GLP-1 GI injury cases into MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. Thousands of cases are transferred.
filingJAMA Study Exposes GI Injury Risks
Sodhi et al. publish landmark JAMA study finding GLP-1 agonists associated with 3.67x gastroparesis risk, 4.22x bowel obstruction risk, and 9.09x pancreatitis risk among weight-loss patients. Triggers wave of lawsuits.
scientificFDA Adds Ileus Warning to Ozempic Label
FDA updates Ozempic labeling to add ileus as a post-marketing adverse reaction. This is the first official acknowledgment of severe GI motility effects beyond nausea and vomiting.
regulatoryFDA Approves Mounjaro (Tirzepatide)
Eli Lilly's Mounjaro (tirzepatide) approved for type 2 diabetes. Later approved as Zepbound for weight loss in November 2023. The dual GIP/GLP-1 agonist produces even greater weight loss than semaglutide.
product-launchFDA Approves Wegovy for Weight Loss
FDA approves higher-dose semaglutide (Wegovy 2.4mg) for chronic weight management. Sales explode as social media drives demand for the "skinny shot." Off-label Ozempic prescriptions for weight loss also surge.
product-launchFDA Approves Ozempic for Type 2 Diabetes
FDA approves semaglutide injection (Ozempic) for type 2 diabetes. Label includes thyroid cancer Black Box Warning and GI side effects but does not name gastroparesis.
product-launchNotable Verdicts & Settlements
Doe v. Novo Nordisk (Projected Bellwether — Gastroparesis)
VerdictFirst bellwether trial expected mid-2026 in MDL 3094. The case will test causation evidence for gastroparesis claims and establish the first jury value for GLP-1 injury cases.
Comparable: Actos (Pioglitazone) Bladder Cancer MDL
Jury VerdictTakeda's Actos bladder cancer MDL produced a $9 billion jury verdict (later reduced) — a comparable pharmaceutical failure-to-warn case involving a diabetes drug with cancer risks the manufacturer concealed.
Comparable: Vioxx Cardiovascular MDL
SettlementMerck's Vioxx global settlement of $4.85 billion for cardiovascular injuries from a drug with suppressed safety data — the gold standard comparable for pharmaceutical failure-to-warn mass tort settlements.
Comparable: Xarelto GI Bleeding MDL
SettlementBayer/J&J settled Xarelto GI bleeding claims for $775 million — a comparable pharmaceutical MDL involving GI side effects of a blockbuster drug.
Comparable: Elmiron Vision Loss MDL
Jury VerdictElmiron (pentosan polysulfate) vision loss MDL resulted in a $54.5 million bellwether verdict — directly comparable to the NAION claims in the GLP-1 NAION MDL (3163).
Comparable: Proton Pump Inhibitor (PPI) Kidney MDL
SettlementPPI kidney injury settlements averaged $300,000 per claim — a comparable pharmaceutical GI drug mass tort. GLP-1 gastroparesis claims are expected to settle in a similar or higher range.
Comparable: Belviq Weight-Loss Drug Cancer MDL
VerdictBelviq (lorcaserin) cancer lawsuits — another weight-loss drug removed from the market for safety reasons — provide a direct comparable for failure-to-warn claims against weight-loss pharmaceutical manufacturers.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Ozempic / GLP-1 Lawsuits Case Page